Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Year range
1.
Arch. cardiol. Méx ; 88(1): 9-15, ene.-mar. 2018. tab, graf
Article in Spanish | LILACS | ID: biblio-1054983

ABSTRACT

Resumen Introducción: La cirugía de revascularización de miocardio (RVM) sigue siendo el gold standard en el tratamiento de la enfermedad coronaria multiarterial. Se ha demostrado que la RVM con ambas arterias mamarias internas (AMI) tiene mejor resultado de sobrevida a largo plazo. Metodología: Investigación retrospectiva de las cirugías de RVM con AMI bilateral, realizadas en el Instituto Nacional Cardiovascular-INCOR-EsSalud entre enero de 2012 a diciembre de 2015. Los objetivos fueron determinar la mortalidad por cualquier causa y los eventos cardiovasculares mayores a 30 días de seguimiento. Resultados: Treinta y seis pacientes fueron operados con AMI bilateral. No tuvimos mortalidad a 30 días. Los eventos cardiovasculares mayores se presentaron en el 5.56% de los pacientes (stroke 0%, infarto de miocardio posquirúrgico 5.56%, necesidad de nueva intervención coronaria 0%). La incidencia de mediastinitis y/o reconstrucción esternal fue de 0%. Siete pacientes tuvieron infección superficial de la herida, no hubo diferencia significativa entre los diabéticos y los no diabéticos (25% vs. 16.66%, OR: 3.3, p = 0.88) o entre los pacientes con o sin sobrepeso (19.23% vs. 20%, respectivamente, OR: 0.95, IC 95%, p = 0.68) para presentar infección de herida. Conclusiones: La RVM con AMI bilateral es un procedimiento seguro, con bajas tasas de mortalidad y de eventos cardiovasculares mayores a corto plazo. © 2016 Instituto Nacional de Cardiología Ignacio Chávez. Publicado por Masson Doyma México S.A. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (https://creativecommons.org/licenses/by-nc-nd/4.0/).


Abstract Introduction: Coronary artery bypass graft (CABG) surgery remains the reference standard in the treatment of multivessel coronary disease. Several studies have shown that CABG with bilateral internal mammary arteries (BIMA) has better results in long-term survival. Methodology: A retrospective study was conducted on CABG surgeries with BIMA from January 2012 to December 2015 in the National Cardiovascular Institute, INCOR, EsSalud, Peru. The objectives were to determine the mortality and major cardiovascular events at 30 days followup. Results: Of the 36 patients subjected to CABG surgery with BIMA, the 30-day mortality was 0%, with major cardiovascular events occurring in 5.56% of patients (Stroke 0%, postoperative myocardial infarction 5.56%, need of new coronary intervention 0%). The incidence of mediastinitis and/or sternal reconstruction was 0%. Superficial wound infection was observed in 7 patients, with there being no significant difference between diabetics and non-diabetics (25% vs. 16.66%, OR = 3.3, P = .88), or between patients with or without overweight (19.23% vs. 20%, respectively,OR = .95; 95% CI, P = .68). Conclusions: CABG surgery with BIMA is a safe procedure, with low rates of mortality and major cardiovascular events in the short-term. © 2016 Instituto Nacional de Cardiología Ignacio Chávez. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/).


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Coronary Artery Disease/surgery , Coronary Artery Bypass/methods , Mammary Arteries/transplantation , Time Factors , Retrospective Studies , Treatment Outcome
2.
J. bras. med ; 101(4): 7-12, jul.-ago. 2013.
Article in Portuguese | LILACS | ID: lil-699658

ABSTRACT

Neste artigo revisaremos o tratamento antiplaquetário e antilipêmico, controle da pressão arterial e controle da frequência cardíaca e sua influência na mortalidade e novos eventos, aplicável a todo paciente portador de doença coronariana crônica.


We review the antiplatelet and hypolipidemic treatment, blood pressure and heart rate control and its influence on mortality and new events, applicable to all patients with chronic coronary disease.


Subject(s)
Humans , Male , Female , Coronary Disease/therapy , Hypolipidemic Agents/administration & dosage , Hypolipidemic Agents/therapeutic use , Platelet Aggregation Inhibitors/administration & dosage , Platelet Aggregation Inhibitors/therapeutic use , Clofibric Acid/therapeutic use , Aspirin/administration & dosage , Diet, Fat-Restricted , Drug Interactions , Heart Rate , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Life Style , Arterial Pressure
SELECTION OF CITATIONS
SEARCH DETAIL